Neoadjuvant Immunotherapy in the Treatment of Renal Cell Carcinoma: A Case Series.

Renal cell carcinoma is a type of urologic cancer that has a poor prognosis, with the majority of these being clear cell renal carcinoma. This subset has a tendency to cause disruptions in the cell cycle, making immune checkpoint inhibitors for adjuvant treatment of renal cell carcinoma the predominant pharmacological approach. Despite this, the use of immune checkpoint inhibitors in this setting is still an area of much research.

Too Hot to Handle: A Case of Fever of Unknown Origin.

Fever of unknown origin (FUO) is defined as a fever higher than 38.3ºC for at least three weeks. It remains a difficult diagnostic challenge and it carries well over 200 differential diagnoses, including infectious, rheumatologic and malignant etiologies.

Utilization of Emicizumab in Acquired Factor VIII Deficiency.

BACKGROUND Acquired hemophilia A (AHA) is a rare autoimmune disease caused by immunoglobulins that bind and inactive factor VIII, thereby predisposing to life-threatening bleeding. Bleeding is typically stabilized by utilizing bypassing agents, such as recombinant factor VIIa (rVIIa). Select case reports have demonstrated the success of alternative prophylaxis for clearance of factor VIII inhibitors through the use of emicizumab, a current FDA approved medication for treatment of congenital hemophilia A.